

(19)
(12)

(KR)
(B1)

(51) 。 Int. Cl.⁷
D21H 21/22
D21H 23/04

(45)
(11)
(24)

2004 03 11
10-0422209
2004 02 27

(21)	10-2001-7004741
(22)	2001 04 14
	2001 04 14
(86)	PCT/US1999/023593
(86)	1999 10 08

(65)	10-2001-0085926
(43)	2001 09 07
(87)	WO 2000/22231
(87)	2000 04 20

[illegible]

AP ARIPO : , , , , , , , 가 ,
 , , ,

[illegible]

EP : , , , , , , , , ,
 , , , , , , ,

,

OA OAPI : , , , , , 가 ,
 , , , , , , ,

(30)	60/104,371	1998	10	15	(US)
------	------------	------	----	----	------

(73) 45202 1

(72) 303
45215

45231 #10 8557

45242 8021

45242 10010

(74)

:

(54)

가 .
;
가 ;
2 4
2
(R₁)_{4-m}-N⁺ -[(CH₂)_n-Y-R₃]_mX⁻

1

1998 10 15 (Vinson) 가 60/104,371

가
가

가
가

가

가
 1993 7 20
 5,228,954 , 1995 4 11
 5,405,499 , 1989 10
 17 (Cochrane)
 4,874,465 1997 8 5
 (U.S. Statutory Invention Registration) H1672 (Her
 mans)
 , 가 1981 11 17 (Carstens) 4,300,981 가
 ,
 ,
) 가 . " "
 , 가 , 가
 , ,
 , ,
 , ,
 4
 2가
 가 , 가 ,
 (Fourdrinier) 가 가
 가 가
 1993 11 23 가 (Phan) (Trokan) 5,264,08
 2 가
 , 가
 ; 가
 , 가
 , 가
 가 가
 1996 1 30
 5,487,813
 ;
 가 가 1991
 10 22 (Ampulski) 5,059,282 가
 (20 % 35 %) 가
 가 가
 , 가
 ,
 ,
 1993 6 1 5,215,626 ; 1
 993 9 21 5,246,545 ; 1996 6 11 (Warner)
 5,525,345 1998 4 1 09/053,31
 9 . 5,215,626
 . 5,246,545 가
 ,
 ,
 ,
 가
 ()
 ,
)

' 가 ;

. :
;
;

" 가
"

가 . 가 가 가
가 " "

, , ,
() 가

0.1 % 10 % 80 g/m²

0.6 g/cc %, 10

: 가 가

1 가 가

', 가 "
(-) 가 ,

, 가 , 가
가 가 , 가
,

" " ,
43 , 65 "

" 23 50 %
. 23 50 % 7 %

0 6 %, 가 0 3 %
5 8 % 가
3 % ()

[illegible]


1967	1	31			3,301,746	, 1976	8	10
(Ayers)			3,974,025	, 1980	3	4		4,191,609
1987	1	20	4,637,859					

[illegible]

Figure 1. The number of people who have been convicted of a crime in the United States, by year and by race/ethnicity. The chart shows that the number of people convicted of a crime has increased significantly over time, particularly for Black and Hispanic populations. The data is as follows:

Year	White	Black	Hispanic
1967	1,310,000	1,000,000	1,000,000
1971	1,330,000	1,000,000	1,000,000
1974	1,350,000	1,000,000	1,000,000
1976	1,380,000	1,000,000	1,000,000
1980	1,420,000	1,000,000	1,000,000
1985	1,470,000	1,000,000	1,000,000
1990	1,520,000	1,000,000	1,000,000
1995	1,570,000	1,000,000	1,000,000
2000	1,620,000	1,000,000	1,000,000
2005	1,670,000	1,000,000	1,000,000
2010	1,720,000	1,000,000	1,000,000
2015	1,770,000	1,000,000	1,000,000
2020	1,820,000	1,000,000	1,000,000


R₂ C₁₄-C₂₂, ;
X -
, R₂ X -
[Swern, Ed. in Bailey's Industrial Oil and Fat Products, Third Edition, John Wiley and Sons(New York 1964)]
6.13 78 % 16 18
" "
() ()
()
2 4
:



Y -O-(O)C-, -C(O)-O-, -NH-C(O)- -C(O)-NH- ;
m 1 3 ;
n 0 4 ;
R₁ C₁-C₆, ;
R₃ C₁₃-C₂₁, ;
X -
, Y -O-(O)C- -C(O)-O- ; m 2 ; n 2 . R₁ C₁
-C₃, R₃ C₁₅-C₁₇ / R₃ C₁₅-C₁₇ / C₁₃-C₁₇ /
R₃ (C₁₇ , R₃) 4
/ 4
, X -
- 4
()
()
()
가 (ADOGEN) SDMC
(Witco Chemical Company)

" " ()
R₁, R₂ R₃,
R₂ C₁₂-C₁₈ / , R₁ R₂ C₁₆-C₁₈ /
, R₃ C₁₃-C₁₇ /
17 / , R₃ C₁₅-C₁₇ /
10 % () , (R₁)₂ -N⁺ - ((CH₂)₂ OH)((CH₂)₂ OC(O)R₃)X⁻

595	;	1996	4	23		5,510,000	;	1995	5	16	
			5,415,737		1995	12	12				(Kimberly-Clark Cor
poration)					0	688	901	A2			.



가

가

25 % 15 % 1
0.1 %
0.3 % 1.0 %
25 100 sec⁻¹
10 200 cp
가
10 (cp) 1000 cp,

가

가

가

가


(pallisade)

가

: M.J. Rosen, Surfactants and interfacial phenomena, Second Edition, pages 125 and 126]).



3 % 2 % 15 %
10 %
/ , 1 , 2
(, 6 , 2
2 , 8 8 18 10 , 15 HLB 50 6
20, 30 , 3 15 , 12
)

a. 3 :




R¹ , 1 , 2
6 , 22 ;

Y' -O-, -N(A)- ;
 A H, R^1 , $-(R^2O)_z-H$, $-(CH_2)_xCH_3$, ;
 x 0 3 ;
 z 5 30 ;
 R^2 $-(CH_2)_n-$ / $-[CH(CH_3)CH_2]-$;
 R^5 -OH -O(R^2O) $_z$ -H ;
 m 2 4 ;
 $b.$ 4 5 :



Y'' N O ;
 R^5 -H, -OH, $-(CH_2)_xCH_3$, $-O(OR^2)_z-H$, $-OR^1$, $-OC(O)R^1$ -CH($CH_2-(OR^2)_z-H$)
 $-CH_2-(OR^2)_{z'}$ -C(O) R^1 ;
 x R^1 ;
 z, z', z'' 5 20 , $z+z'+z''$ 5 20 , 가
 Y'' 가 O 5 , R^5 -H , 2 R^5 -O(R^2O) $_z$ -H , R^1 8 R^5 -CH(C
 $H_2-(OR)_z-H$)-CH $_2-(OR^2)_{z'}$ -C(O) R^1 (, $z+z'+z''$ 8 20) , R^1 8 20
 $c.$ 6 :




R^2 R^1 H, C_1-C_4 , C_1-C_4 ;
 C_5-C_{31} ;
 Z 3 ;
 R^1 H - - .

(1) _____
 (,) , / 1 2 , ,
 () 30 ,
 6 22
 8 18 , 가 6
 30 15 1
 12


70 (21) /
 (Shell) (Neodol,) 91-8, 23-5, 25-9, 1-9, 25-12, 1-9 45-13,
 (BASF) (Plurafac,) B26 C-17 ICI (Surfactants) (U
 Brij,) 76 35 (Igepal,) CO-620 CO-710, (Dowfax,
 (Surfonic,) N-120, (Triton,) N-111 N-150, (Dow) (U
 nion Carbide) (Lutensol,) AP9 AP14
) 9N5
 (2) _____

, 1 2
 , 50 (, /)
 1 2 2 -
 , 6 22
 , 3 15 , 1 2 가 50
 , 가
 8 18 70 (21)
 /
 (Berol,) 397 303 (Akzo) (Ethomeens,) C/20, C25, T/25, S/20
 , S/25 (Ethodumeens,) T/20 T25
 , -
 7 :






R^1 , 1 , 2 -
 ; 6 22 , 8 18 ,
 8 15
 $R^2 - (CH_2)_n - (, 1 < n 3) / - [CH(CH_3)CH_2] -$
 ;
 $Y - O - , -N(A)_q - , -C(O)O - , - (O)N(A)_q - , -B-R^3 - O - , -B-R^3 - N(A)_q - , -B-R^3 - C(O)O - , -B-R^3$
 $- N(O)(A) -$
 $A H, R^1 , - (R^2 - O)_z - H , - (CH_2)_x CH_3 ,$
 $x 0 3 ;$
 $B - O - , -N(A) - , -C(O)O -$
 $R^3 R^2 ,$
 $C 1-4 . z 5 30 . p$
 $1 2, 1 , m 1 2, 1 ,$
 $q m 1 p가 1 2 5 z 30 q가 1 0 p가 2 q 0 m$
 $1 p가 1 2 9 z 12 y 0 .$
 (3) _____

, 1 2
 , , , -
 , -
 50 , 30 (, /)
 6 22 , 30
 가 50 , 15 , 가
 6 12 가 8 18
 ICI (Tween,) 40, 60 80 .


$$R^{-1} \begin{pmatrix} 6 & 1 \\ 22 & 2 \end{pmatrix} = -$$
$$\begin{array}{l} \text{Y}' \quad -\text{O}-, -\text{N}(\text{A})- \\ \text{A} \quad \text{H}, \text{R}^1, -(\text{R}^2\text{O})_z -\text{H}, -(\text{CH}_2)_x \text{CH}_3, \\ x \quad 0 \qquad 3 \end{array} \quad ;$$
$$\begin{array}{l} \text{R}^2 \text{-(CH}_2\text{)}_n\text{-} / \text{-[CH(CH}_3\text{)CH}_2\text{]-} \\ \text{R}^5 \text{-OH} \quad \text{-O(R}^2\text{O)}_z\text{-H} \end{array}$$

m 2 4 . 4 5 :


$$\begin{aligned} & \text{Y}'' \text{N} \text{O} ; \\ & \text{R}^5 - \text{H}, -\text{OH}, -(\text{CH}_2)_x \text{CH}_3, -(\text{OR}^2)_z - \text{H}, -\text{OR}^1 -, -\text{OC}(\text{O})\text{R}^1 - \text{CH}_2 (\text{CH}_2 - (\text{OR}^2)_z - \\ & -\text{H}) - \text{CH}_2 - (\text{OR}^2)_z - \text{C}(\text{O})\text{R}^1 \quad . \text{x}, \text{R}^1 \quad \text{R}^2 \quad \text{D} \\ & , z, z' \quad z'' \quad 5 \quad 20 \quad , \quad z+z'+z'' \quad 5 \quad 20 \quad . \\ & \text{O}(\text{R}^2\text{O})_z - \text{H} \quad , \quad \text{R}^5 - \text{CH}(\text{CH}_2 - (\text{OR}^2)_z - \text{H}) - \text{CH}_2 - (\text{OR}^2)_z - \text{C}(\text{O})\text{R}^1 (\quad , z+z'+z'' \\ & \quad 8 \quad 20 \quad) \quad , \text{R}^1 \quad 8 \quad 20 \quad 9 \quad ; \end{aligned}$$



R^7 , H, C₁-C₄, C₁-C₄, C₁, C₂, 2-
 , 2-, C₁-(), ;
 R^6 C₅-C₃₁, C₇-C₁₉, C
₉-C₁₇, 가 C₁₁-C₁₇; W
 (,) . W
 ; W
 $-\text{CH}_2\text{OH}$, $-\text{CH}(\text{CH}_2\text{OH})-(\text{CHOH})_n-\text{CH}_2\text{OH}$, $-\text{CH}_2-(\text{CHOH})_2(\text{CHOR}')(\text{CHOH})-\text{CH}_2\text{OH}$ (, n
 3 5) , R' H -
 . 가 n 4 , $-\text{CH}_2-(\text{CHOH})_4-\text{CH}_2\text{O}$. W

R⁶ N-, N-, N-, N-, N-, N-, N-2-, N-1-
N-2-
R⁶-CO-N<


W 1-, 2-, 1-, 1-, 1-, 1-
1-

(4) 4

4
50 (/) 1
2 1 2 6 50 22 1
2 , 1 , 2 4
6 22
8 18 50 4 ,
5 12 3 20 , 가
1 2 70 (21)
/ (Ethoquad,) 18/25, C/25 O/25 (Variquat,) 66(16
()
10 :



R¹ R² D ;
Y N + -(A)_q, -(CH₂)_n-N + -(A)_q, -B-(CH₂)_n-N + -(A)₂, -()-N + -(A)_q -(B-)-N
+ -(A)_q ;
n 1 4
A H, R¹, -(R²O)_z-H, -(CH₂)_xCH₃, ; x 0 3
; B -O-, -NA-, -NA₂, -C(O)O- -C(O)N(A)- ; R² ; q 1
2 ; X -
m 1 p가 1 2 5 z 50 m 1 p가 1
2 7 z 20 ; 가 m 1 p가 1 2 9 z 12
(5) 11 :



R C₇₋₂₁, C₇₋₂₁, C₇₋₂₁, C₇₋₂₁.
R C₈₋₁₈
R¹ -CH₂-CH₂-, R² C₃-C₄, C₃-C₄ ;
R² -CH(CH₃)-CH₂- R¹ R² 1
4 -CH(CH₃)-CH₂- 4 12 -CH₂-CH₂-
R¹ R² 4:1 8:1
R² (, -C(CH₃)H-CH₂-)
CH₂-CH₂-
R³ C₁-C₄, C₃-C₄ ;
R⁴ C₁-C₄, C₃-C₄ ; m 2
n 0, R⁴

$m+n$ 2 m 1 2 , n 0 1 , x 0 m 1 n 1 $-(R^1 O$
 $)_x (R^2 O)_y R^3]$ R^4 50, 3 y
 5, 10 y 0 10, 0 y 가 0 y
 1 4 ,
 (Amidox,) C_5 (Rewopal,) C_6 , (Stepan)
 (Ethomid,) O/17 (
) HT/60 .

가 가 (), pH (
 orning) 2310 (, (Dow C
)

(Avecia, Inc.) 가 (Pro
 xel) GXL 0.1 %
 pH
 pH 2.5 4.0, 2.5 3.5,
 2.5 3.0

060 (Clariant Corporation) HOE S 4
 -X 가 가 -가 (CIBA-GEIGY) (Tinopal) CBS
 UV 가

45 % 10 % 50 % 25 %
 가 , 30 % 40 %
 1 % 15 %, 2 % 10 %
 5 % 25 % 가 2 % 30 %, pH

(1)
 1

가). (25 %) 165 (75) 가 (가 , 가
 150 (65) 가 , 가
 가

가 . (4 가
 .) 가 (2.5 %) , 가
 (25 %) 가

1	
	100 %
1	0.6 %
2	0.2 %
3,5	1.1 %

가 , 가
100 50
90 , 70 90
1998 9 11) (, 2 가 60/099,885 ()
; .
가 60/099,885 ,
1 , (10) 가 (5)
(14) (15) (15) 0.1 % 8 %, (15) 0.1 %
5 %, 0.1 % 3 %
110 psi(750 kPa) 170
가 120
60 , 가
가 가
가 가
가 가
가 가
((Anilox)),
1998 9 28 5,814,188
(,) (,)
()
()
1999 2 22 09/
258,497 , 1999 2 26 (Solberg) 09/258,498 , 1999
5 5 (Ficke) 09/305,765 1999 8 20
09/377,661
:
1. (1) 0.5 %
, 1.5 %
가
2. 가 가
가 , 0.2
0.3 PSU (Panel Score Unit: PSU) 0.5 PSU

2 () (,
). (,
) 가
 " "
 " "
 " "
 4
 :
 : " "
 16 20 4 가
 2
 2 ((, 12 22
), (a- ; ") 가 (, 12 22
 : " (, 12 22
) " (, 12 22
 1997 3 4 (Roe) 5,607,760
 12 22
 (ETHOMID)
 (Akzo-Nobel chemicals, Inc.)
 가

1
 가
 2
 3 % NSK
 0.3 % 750 750() 1 % , NSK
 NSK 가
 3 % (RediBOND) 5320() 2 %
 0.15 %
 , NSK
 NSK NSK NSK 0.2 %
 NSK
 15 %
 ()
 45x52 10 mil
 40 % , in 2 562 가
 가 28 %

62 %

0.125 %

0.1 %

96 % 가

25 81

350 (177) 800 fpm() (244 m/)

2 SU14 ((Air cap) #73328 (Fluid cap) #2850 가

m/) 18 % % , 656 fpm(200

1. 400 4

DXP-505-91 67 % 4 (33 % PEG 400) SDMC

2. 23-5,

3.

4. 10 % (DC2310).

5.

6. -가 가 (Tinopal) CBS-X

7. HOE S 4060

가 가 75 가 (23-5),

PEG 400 가 65 가 4 pH , 4

가 2.5 % 가 , 가

(25 %) 가

40 %	4
38 %	
19 %	PEG 400
2 %	23-5
0.6 %	CaCl ₂
0.5 %	
0.2 %	
0.02 %	HCl
98 ppm	

25 100 sec⁻¹ 3

00 cp

00 ft² 12.8 lb 30

2

e) ((Charmin Ultra,), 가 (Procter Gambi

-0.12 PSU +1.34 PSU

1.46 PSU

2

[1]

	(%)
4	41
	39
PEG 400	19
CaCl ₂	0.5
	0.5
	0.2
HCl	0.02

1 %, 2 %, 3 % 4 %

가 2 , HLB()

[2]

비이온성 계면활성제	HLB	농도(%)	점도(센티포이즈)
네오돌 23-3 ¹	7.9	0	$1.8 \times 10^{+4}$
		1	6774
		2	4375
		3	1549
		4	1365
네오돌 23-5 ¹	10.7	0	2150 [*]
		1	335
		2	260
		3	644
		4	1285
네오돌 91-8 ¹	13.9	0	$1.8 \times 10^{+4}$
		1	166
		2	1583
		3	9×10^3
		4	8×10^3
서포닉 N-120 ²	14.1	0	6103 [*]
		1	193
		2	704
		3	7595
		4	9×10^3
아코논(Acconon) CC-6 ³		0	6103 [*]
		1	450
		2	421
		3	1194
		4	1.7×10^4
트윈 60 ⁴	14.9	0	$6.4 \times 10^{+4}$
		1	215
		2	367
		3	652
		4	2043
플루라팍 B25-5 ⁵	12.0	0	1029 [*]
		1	442
		2	2100
		3	2.9×10^4
		4	1.1×10^5

* 이론에 의해 제한되지 않으면서, 발명자는 점도의 변화가 사용되는 연화 활성 성분의 고 농도로 인한 안정한 액정상의 간헐적인 형성 때문이라고 생각한다. 상기 나타난 바와 같이, 이중층 붕괴제의 첨가는 액정상의 구조를 방해하여 점도를 감소시키는 것으로 생각된다.

1. 텍사스주 휴스턴 소재의 쉘 케미칼로부터의 에톡실화 지방 알콜.
2. 텍사스주 휴스턴 소재의 헨츠만 코포레이션으로부터의 에톡실화 알킬페놀.
3. 오하이오주 컬럼버스 소재의 아비텍 코포레이션(Abitex Corp.)으로부터의 에톡실화 카프릭 /카프릴릭 글리세리드.
4. 노스캐롤라이나주 샬럿 소재의 헨켈 코포레이션(Henkel Corp.)으로부터의 POE(20) 소르비탄 모노스테아레이트.
5. 뉴저지주 마운트 올리브 소재의 바스프 코포레이션(BASF Corp.)으로부터의 개질된 옥시 에틸화 직쇄 알콜.

가

4

(QAC)

(

-NaDDS)

QAC

가

1

:

A) 500 ml

가

B) 40 ml

-

(

(Gallard-Schlesinger Industries, Inc.)

)

가

C) 46 ml 5 N H₂ SO₄

가

D)

NaDDS

1 :
 A) () (Aldrich Chemical Co.)
 0.1154 g NaDDS
 B) 0.0004 N

1. 0.5 g 0.1 mg
2. 150 ml , 20 ml
3. 가
4. 35 ml 가
5. 10 ml QAC
6. 0 가 3
7. 0.3 ml 가 , 30
8. 가 0.3 ml
9. 0.05 ml
10. 1 QAC

$$[(\text{NaDDS의 ml-X}) \times Y \times 2] / \text{샘플 중량(g)} = \text{QAC 톤당 파운드}$$

X QAC가
 Y 1.00 ml NaDDS가 QAC mg (, QAC, (-
) Y 0.254).

가 가 95 g/in² (15.5 g/cm²)

TAPPI #T402OM-88
 24 10 35 % 22 40
 24 48 52 % 22 24

가
 (American Society For Testing and Materials) 1968 ["Manual on Sensory Testing Methods", ASTM Special Technical Publication 434]

1. X가 Y +1 , Y가 X -1
2. X가 Y +2 , Y가 X
3. X가 Y -2 ; +3 , Y가 X -3
4. X가 Y -4 ; +4 , Y가 X

PSU .
가 ,
0- 0 PSU
0.2 PSU가
+ -

(Intelect) II (Thwing
-Albert Instrument Co.)) 1
TAPPI #T402OM-88
2 48 52 %
22 24
, 5 4 가 (1
) , 2 4가
3 (가 JDC-1-10 JDC-1-12,
) 4 1 3
2 4가
2 1" 1 3 . 2 1" 2 4
, 4 1" 4 1" 가 5 가 (15" x
/) , (가 JDC-1-10 JDC-1-12,
15" 15" 가 8 15" x
2 48 52 % 22 24
가 8 15" x 15" , 가 7" 1" x 7"
4 가 7" 1" x 7" 4 가
가 JDC-1-10 JDC-1-12,
: 4
, 가 8 가 7" 1" x 7" , 4
, 가 8 가 7" 1" x 7"

II (-
) , - II
in 20.0 g 4.00 in/ , 1 2 2.00
, 1.00" 0.025"
가 25 % 75 % , 5
000 g 1250 g(5000 g 25 %) 3750 g(5000 g 75 %)
125 g 375 g 5000 g 1
0 %
가 2
2 , 5 g 가 ,
2 3 가 ,
가 가 g
가 g

가

가

가

g/in

m

가

가

100(s⁻¹)

가

SR500((Rhe

ometrics Scientific, Inc.)

: 25 mm

가

: 0.5 mm

: 20

: 0.2455 cm³

: 10 /cm²

: 1,000 /cm²

가: 20 25 /cm² 가

가

가

x 100(s⁻¹) (s⁻¹), y ((P)) P y (/cm²) (cP)

(

가

(57)

1.

가

0.1 8%



2.

1

2

(R₁)_{4-m}-N⁺-[(CH₂)_n-Y-R₃]_mX⁻

Y -O-(O)C-, -C(O)-O-, -NH-C(O)- -C(O)-NH- ;

m 1 3 ;
 n 0 4 ;
 R_1 C_1 - C_6 , , ,
 R_3 C_{13} - C_{21} , , ,
 X - - .
3.
1 2 가 가
4.
3 ,
가 가
5.
1 2 ,
, .
6.
1 2 ,
가 A C :
A. 3
 R^1 - $C(O)$ - Y' - $[C(R^5)]_m$ - $CH_2O(R^2O)_zH$
 $[Y' - O-, -N(A)-$, A H, R^1 , $-(R^2-O)_z-H$, $-(CH_2)_xCH_3$,
 $x=0, 3$;
 R^1 , 1, 2 -
 R^5 -OH - $O(R^2O)_z-H$;
 R^2 - $(CH_2)_n-($, $n=1, 4)$ / - $[CH(CH_3)CH_2]-$
;
 $m=2, 4$;
 $z=5, 30$];
B. a b :
a. 4 5 :
4


 $[Y''N, O$;
 R^5 -H, -OH, $-(CH_2)_xCH_3$, $-O(OR^2)_z-H$, $-OR^1$, $-OC(O)R^1$ - $CH(CH_2-(OR^2)_z)-H$
 $)-CH_2-(OR^2)_{z'}-C(O)R^1$;
 R^1 , 1, 2 - ,
 R^2 - $(CH_2)_n-($, $n=1, 4)$ / - $[CH(CH_3)CH_2]-$;
 $x=0, 3$;
 $z, z'=z''=5, 20$];
b. 6 :

$$R^2 - C(O) - N(R^1) - Z$$

$$\left[\begin{array}{l} R^1, H, C_1 - C_4, \\ R^2, C_5 - C_{21} \\ Z, 3 \end{array} \right];$$

$$C. \quad 10 \quad :$$

$$\{R^1_m - Y - [(R^2 - O)_z - H]_p\} + X -$$

$$\left[\begin{array}{l} R^2, -(CH_2)_n - / - [CH(CH_3)CH_2] - \\ Y - N + -(A)_q, -(CH_2)_n - N + -(A)_q, -B - (CH_2)_n - N + -(A)_2, -() - N + -(A)_q - (B -) - \\ N + -(A)_q, A, H, R^1, -(R^2 O)_z - H, -(CH_2)_x CH_3, \\ 3; \\ R^1, 1, 2, 6 \\ 22; \\ n, 1, 4; \\ q, 1, 2; \\ z, 5, 50; \\ m, 1; \\ p, 1, 2; \\ X - \end{array} \right] \text{가}] .$$

7.

$$6 \quad , \quad 8 \quad 18 \quad 8 \quad 18$$

$$, 3 \quad 15$$

8.

$$1 \quad 2 \quad , \quad 2 \quad 15 \quad \%$$

9.

10.

